Today AVEO Oncology announced that it has submitted a New Drug Application (NDA) to the U.S.Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC).

Advanced RCC, or kidney cancer, is the ninth most commonly diagnosed cancer in men and women in the U.S.[1] Worldwide it is estimated that more than 250,000 people are diagnosed and more than 100,000 people die from the disease each year.[2] RCC accounts for more than 90% of all kidney cancers.[3]

Currently available therapies provide less than one year of median PFS(progression-free survival)in treatment naive patients and are associated with significant toxicities.[4] These toxicities not only lead to high rates of dose reductions and interruptions (potentially compromising efficacy), but also can impact a patient?s quality of daily living.[5]

Optimizing VEGF

Tivozanib is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off target toxicities. The drug candidateis an oral, once-daily, investigational tyrosine kinase inhibitor for which positive results from a Phase III clinical study in advanced renal cell carcinoma have been reported. Tivozanib is also under evaluation across a broad range of solid tumors, including metastatic colorectal cancer and metastatic breast cancer.

Advertisement #3


The NDA submission is based on results of the global Phase III TIVO-1 (Tivozanib Versus Sorafenib in 1st line Advanced RCC) trial, a randomized superiority-designed pivotal trial evaluating the efficacy and safety of tivozanib compared to sorafenib in 517 patients with advanced RCC who had no prior treatment with a systemic therapy, as well as data from 17 clinical studies involving over 1,000 subjects who received tivozanib. In TIVO-1, tivozanib demonstrated a statistically significant improvement in progression-free survival (PFS) versus sorafenib, an approved targeted agent, and a favorable tolerability profile.

Results from the study were first presented in early June 2012 at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting in Chicago, IL.


[1] U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999?2007Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2010.
[2] Cancer Research UK. Cancer Statistics
[3] American Cancer Society. Renal Cell carcinoma Overview – What is Kidney Cancer?
[4] Bhargava, P., Robinson, M. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep 2011 Apr;13(2):103-11
[5] Ravaud, A. How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Annals of Oncology 20 (Supplement 1): i7?i12, 2009

Copyright ? 2012 InPress Media Group/Sunvalley Communication. All rights reserved.
Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.

Advertisement #5